Remote magnetic navigation for ventricular tachycardia ablation: comparative outcomes

Ventricular tachycardia (VT) ablation is technically demanding because the arrhythmogenic substrate may be extensive, intramural, epicardial, or difficult to reach with a stable catheter. Remote magnetic navigation (RMN) changes the operator’s position and control method by using external magnetic fields to steer a specialised catheter, usually alongside a motorised advancement system. The potential advantages include precise movement, reduced fluoroscopy exposure, and less physical strain during long procedures.

The clinical question is not whether RMN can produce elegant catheter motion. It is whether remote magnetic guidance achieves meaningful improvements compared with conventional manual ablation, including acute procedural success, VT recurrence, complications, procedure duration, radiation exposure, and resource use. For Australian electrophysiology services, those outcomes must also be considered alongside equipment availability, referral distances, workforce requirements, and the regulatory environment.

Why navigation strategy matters

Manual VT ablation depends heavily on catheter stability, sheath support, operator experience, and the anatomy of the target chamber. In scar-related VT, the operator may need to map multiple circuits, interpret pace mapping and entrainment, and deliver lesions across a broad substrate. Haemodynamic intolerance can limit mapping time, while repeated ventricular ectopy or induction of sustained VT may require rapid intervention.

RMN uses magnetic fields to orient a soft-tipped catheter, potentially improving contact in challenging locations. The system can make small, reproducible movements and may reduce the need for forceful catheter manipulation. This is particularly relevant when working near the ventricular outflow tracts, papillary muscles, or other regions where stability and approach angle are difficult. The anatomical issues involved in these cases are discussed in outflow tract challenges.

The technology does not remove the need for operator judgement. Mapping strategy, substrate interpretation, anticoagulation, vascular access, imaging, anaesthesia, and management of haemodynamic deterioration remain central. RMN is a navigation platform, not an independent treatment decision-maker.

Comparative procedural outcomes

Published comparisons between RMN and manual catheter ablation have often involved retrospective cohorts, single-centre experiences, or mixed populations. The results therefore vary according to VT mechanism, underlying cardiomyopathy, use of epicardial access, operator learning curve, and the definition of procedural success. A direct comparison between platforms is difficult when one group includes predominantly idiopathic VT and another includes advanced scar-related disease.

Acute elimination of the clinical VT is generally achievable with either approach in experienced centres. RMN may offer particular value when a stable catheter position is difficult to maintain or when the target lies in a region requiring repeated, fine adjustments. However, available evidence has not consistently shown a large, universal improvement in acute success over manual ablation. In complex substrate cases, the quality of mapping and lesion delivery may matter more than the steering mechanism alone.

Long-term VT recurrence remains the most important comparative endpoint. Recurrence is influenced by progressive cardiomyopathy, incomplete substrate modification, new arrhythmogenic circuits, medication changes, and implantable cardioverter-defibrillator programming. Some series report favourable freedom from recurrent VT after RMN, while others show outcomes broadly comparable with manual ablation. These differences should be interpreted cautiously because patient selection and procedural strategy are rarely identical.

Safety, radiation and workflow

A major rationale for RMN is the possibility of reducing fluoroscopy use. The operator can work away from the radiation field, which may lower occupational exposure over a career. The patient may also benefit when magnetic navigation is integrated with electroanatomical mapping and intracardiac echocardiography. Radiation reduction, however, depends on the whole laboratory workflow, not simply on the presence of a magnetic system. Practical mitigation approaches are outlined in this review of radiation exposure.

Procedural duration is less predictable. RMN may shorten navigation and mapping in selected anatomies, but system docking, image integration, catheter exchanges, troubleshooting, and operator familiarity can offset that benefit. Early cases may take longer, while mature programmes may achieve more efficient workflows. Manual ablation can also be faster when the target is straightforward, the chamber is easily accessible, and the operator has strong catheter control.

Complication profiles appear broadly acceptable, but no platform eliminates procedural risk. Vascular injury, pericardial effusion, thromboembolism, cardiac perforation, anaesthetic complications, and stroke remain possible. A softer catheter may reduce the likelihood of traumatic contact in some settings, although lesion formation can be limited by lower contact force and reduced irrigation characteristics. The balance between atraumatic navigation and adequate energy delivery must be assessed for each substrate.

Which ventricular tachycardia is most suitable

RMN may be especially useful for idiopathic ventricular arrhythmias arising from locations where catheter stability is difficult, including the outflow tracts and certain para-Hisian or papillary muscle regions. It may also help in patients for whom prolonged manual manipulation would be physically demanding or technically hazardous. A soft catheter can navigate curves and reach targets with less aggressive contact, although the final ablation strategy still depends on tissue depth and arrhythmia mechanism.

Scar-related VT after myocardial infarction or non-ischaemic cardiomyopathy presents a more complex test. The substrate may extend across the endocardium, mid-myocardium, or epicardium, and the clinical VT may be poorly tolerated. RMN can support stable point-by-point mapping and may facilitate work in difficult ventricular geometry, but it cannot overcome an inaccessible intramural circuit or replace epicardial ablation when the substrate lies outside the endocardium.

Patient selection should therefore include imaging, left ventricular function, the likely mechanism of VT, prior procedures, device status, and the feasibility of haemodynamic support. In Australia, referral decisions can be affected by geography: a patient from regional New South Wales, northern Queensland, or Western Australia may need to travel to Sydney, Brisbane, Melbourne, or Perth for advanced ablation. A platform that reduces repeat procedures could have value, but travel burden should be measured rather than assumed.

Evidence gaps and Australian implementation

The strongest evidence would come from prospective, multicentre comparisons using consistent definitions of acute success, VT storm, hospitalisation, ICD therapies, mortality, and quality of life. Existing studies frequently have limited sample sizes and short follow-up. They may also compare different generations of catheters, mapping systems, and energy settings. Cost-effectiveness evidence is similarly limited, particularly for public hospitals balancing capital expenditure against procedure volume and workforce capacity.

RMN systems require substantial investment, dedicated laboratory design, technical support, and staff training. The Australian market is concentrated in high-volume tertiary electrophysiology centres, so access is unlikely to be uniform across states. Public and private pathways may differ in waiting times, referral patterns, and access to complex ventricular procedures. Long-distance travel and the need for accommodation or family support can influence whether a patient proceeds with an intervention and whether follow-up is completed.

Regulatory and safety obligations also shape implementation. Devices must meet Australian Therapeutic Goods Administration requirements, while radiation protection is governed through national guidance and state or territory arrangements, including local licensing and compliance processes. Hospitals must also account for magnetic-environment safety, implantable device interactions, emergency access, infection control, and documentation of training. These requirements are manageable, but they add to the real-world cost of adopting remote navigation.

Selecting endpoints that matter clinically

A meaningful comparison should go beyond fluoroscopy time and acute procedural success. Clinicians should examine freedom from appropriate ICD therapy, recurrent VT storm, hospital readmission, antiarrhythmic drug burden, transplant-free survival, and patient-reported health status. Procedure duration, anaesthetic time, vascular complications, pericardial events, and the need for mechanical circulatory support are also relevant.

Economic outcomes deserve a broader perspective. A longer initial procedure may still be worthwhile if it reduces repeat ablation, intensive care admission, or recurrent shocks. Conversely, a technically impressive procedure may provide little value if the patient has advanced heart failure and the arrhythmogenic substrate is likely to progress. Analyses should include equipment depreciation, maintenance, staffing, training, travel, and follow-up across the health system.

Research teams should report whether RMN was used for endocardial, epicardial, or combined procedures; whether the operator had completed the learning curve; and how mapping and ablation endpoints were defined. Subgroup reporting for ischaemic cardiomyopathy, non-ischaemic cardiomyopathy, idiopathic VT, and outflow tract arrhythmias would make results more transferable. Clinicians and trainees can follow developing evidence through the journal’s arrhythmia article collection.

Remote magnetic navigation is best viewed as a specialised option within a broader VT service. Its strongest advantages may involve catheter stability, operator radiation protection, and access to selected anatomically difficult targets. Its superiority over manual ablation is not established across every clinical setting, and recurrence remains driven by substrate biology as much as by navigation technology.

Australian centres considering or expanding RMN programmes should prospectively audit outcomes, compare them with contemporary manual cases, and include patient travel, resource use, and quality of life in the assessment. Researchers, electrophysiologists, and trainees can strengthen the evidence base by publishing transparent comparative data and by using clinically meaningful endpoints that reflect what patients and health services experience after the procedure.